We are live on
!
Find out more
MU
Mirova US Portfolio holdings
AUM
$8.81B
1-Year Est. Return
21.38%
This Fund
S&P 500
This Quarter
Est. Return
+4.72%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
–
AUM
$9.96B
AUM Growth
+$57.9M
(+0.58%)
Cap. Flow
-$243M
Cap. Flow
% of AUM
-2.44%
Top 10 Holdings %
Top 10 Hldgs %
51.82%
Holding
43
New
7
Increased
6
Reduced
30
Closed
–
Top Buys
| 1 |
Lowe's Companies
LOW
|
+$236M |
| 2 |
Broadcom
AVGO
|
+$211M |
| 3 |
Vertiv
VRT
|
+$136M |
| 4 |
Boston Scientific
BSX
|
+$134M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$5.55M |
Top Sells
| 1 |
Roper Technologies
ROP
|
+$237M |
| 2 |
NVIDIA
NVDA
|
+$206M |
| 3 |
Microsoft
MSFT
|
+$132M |
| 4 |
American Water Works
AWK
|
+$113M |
| 5 |
Ecolab
ECL
|
+$103M |
Sector Composition
| 1 | Technology | 40.54% |
| 2 | Healthcare | 17.09% |
| 3 | Industrials | 15.17% |
| 4 | Consumer Discretionary | 10.72% |
| 5 | Financials | 8.52% |
Similar funds
MERSOM
CFB
MOACM
SWP
CB
WT
OAM
PEA
Mirova US's Q4 2025 Portfolio in Review
As of Q4 2025, Mirova US held 43 positions worth $9.96B, up 0.58% from $9.9B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Mirova US's Q4 2025 filing shows 7 new, 6 increased and 30 reduced positions. Its largest new stake was Lowe's Companies: 981,128 shares worth $237M. The largest sale was Roper Technologies, an estimated $237M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 45% a quarter earlier, followed by Healthcare and Industrials.
- Mirova US's largest Q4 2025 buy was Lowe's Companies: 981,128 shares worth $237M.
- Mirova US added most to Broadcom in Q4 2025, an estimated $211M increase.
- Mirova US's biggest Q4 2025 reduction was Roper Technologies, cutting an estimated $237M.
- Mirova US's ten largest holdings make up 52% of its $9.96B portfolio in Q4 2025.
- Mirova US opened 7 new positions and closed 0 in Q4 2025.
- Mirova US's portfolio value rose 0.58% quarter-over-quarter to $9.96B.
Based on Mirova US's 13F filing for Q4 2025, filed 11 Feb 2026.